Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Samantha Kendrick

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentBiochemistry & Molecular Biology, College of Medicine
Address4104 Outpatient Circle
Mail Slot # 516
Little Rock AR 72205
Phone501-526-6000
ORCID ORCID Icon0000-0002-7782-7415 Additional info
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentPathology, College of Medicine


    Collapse Affiliation 
    Collapse member of
    American Society of Hematology
    The G4 Society

    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Director, Summer Undergraduate Research Program (SURF)

    Collapse awards and honors
    2023Outstanding Mentor Award, Graduate School, UAMS
    2023Red Sash Honoree, College of Medicine, UAMS

    Collapse Research 
    Collapse research activities and funding
    2341253     (EOFF, ROBERT L)May 1, 2024 - Apr 30, 2028
    National Science Foundation
    Replication of G-quadruplex DNA by translesion polymerases
    Role: Principal Investigator
    CA210788     (KENDRICK, SAMANTHA)Sep 15, 2022 - Sep 14, 2025
    DoD
    Targeting unique DNA structures to repress oncogenic signaling in lymphoma
    Role: Principal Investigator
    W81XWH 22 1 1031     (KENDRICK, SAMANTHA)Sep 15, 2022 - Sep 14, 2025
    US Department of Defense
    Targeting unique DNA structures to repress oncogenic signaling in lymphoma
    Role: Principal Investigator
    W81XWH2211031     (KENDRICK, SAMANTHA)Sep 15, 2022 - Sep 14, 2025
    US Department of Defense
    Targeting unique DNA structures to repress oncogenic signaling in lymphoma
    Role: Principal Investigator
    P20GM121293     (TACKETT, ALAN)Jul 1, 2020 - Jun 30, 2022
    NIH/NIGMS
    Targeting oncogenic regulation through unique DNA structures in lymphoma
    Role: Principal Investigator
    P20GM203635     (SMELTZER, MARK)May 1, 2019 - Apr 30, 2020
    NIH/NIGMS
    Impact of HIV on lymphomagenesis
    Role: Principal Investigator
    Seeds of Science FY19     (BYRD, ALICIA K)Feb 1, 2019 - Jan 31, 2020
    UAMS Internal Research Awards
    Seeds of Science Pilot award
    Role: Principal Investigator
    ACRI # 037191     (KENDRICK, SAMANTHA)Jul 1, 2018 - Jun 30, 2019
    UAMS ACHRI Flow Through
    No FP attached
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329. PMID: 37816504.
      View in: PubMed
    2. Chen J, Wang Z, Phuc T, Xu Z, Yang D, Chen Z, Lin Z, Kendrick S, Dai L, Li HY, Qin Z. Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. PLoS Pathog. 2023 01; 19(1):e1011089. PMID: 36638143.
      View in: PubMed
    3. Swafford K, Acharya B, Xu YZ, Raney T, McCrury M, Saha D, Frett B, Kendrick S. Targeting a Novel G-Quadruplex in the CARD11 Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. Genes (Basel). 2022 06 25; 13(7). PMID: 35885931.
      View in: PubMed
    4. Chen J, Barrett L, Lin Z, Kendrick S, Mu S, Dai L, Qin Z. Identification of natural compounds tubercidin and lycorine HCl against small-cell lung cancer and BCAT1 as a therapeutic target. J Cell Mol Med. 2022 05; 26(9):2557-2565. PMID: 35318805.
      View in: PubMed
    5. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817. PMID: 34807986.
      View in: PubMed
    6. Chen J, Dai L, Kendrick S, Post SR, Qin Z. The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Antimicrob Agents Chemother. 2022 03 15; 66(3):e0239521. PMID: 35041508.
      View in: PubMed
    7. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344. PMID: 34050985.
      View in: PubMed
    8. Mohan M, Kumar M, Samant R, Van Hemert R, Tian E, Desai S, van Rhee F, Thanendrarajan S, Schinke C, Suva LJ, Sharma S, Milad M, Kendrick S, Zangari M. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 05; 146:115876. PMID: 33556629.
      View in: PubMed
    9. Brown SL, Kendrick S. The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure. Pharmaceuticals (Basel). 2021 Jan 27; 14(2). PMID: 33513764.
      View in: PubMed
    10. Shponka V, Reveles CY, Alam S, Jaramillo M, Maguire A, Rimsza LM, Kendrick S. Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV. AIDS. 2020 11 15; 34(14):2025-2035. PMID: 32773475.
      View in: PubMed
    11. Xu YZ, Jenjaroenpun P, Wongsurawat T, Byrum SD, Shponka V, Tannahill D, Chavez EA, Hung SS, Steidl C, Balasubramanian S, Rimsza LM, Kendrick S. Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma. NAR Cancer. 2020 Dec; 2(4):zcaa029. PMID: 33094287.
      View in: PubMed
    12. Storey AJ, Naceanceno KS, Lan RS, Washam CL, Orr LM, Mackintosh SG, Tackett AJ, Edmondson RD, Wang Z, Li HY, Frett B, Kendrick S, Byrum SD. ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. Mol Omics. 2020 08 01; 16(4):316-326. PMID: 32347222.
      View in: PubMed
    13. Chen J, Kendrick S, Qin Z. Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas. Viruses. 2019 12 16; 11(12). PMID: 31888174.
      View in: PubMed
    14. Maguire A, Chen X, Wisner L, Malasi S, Ramsower C, Kendrick S, Barrett MT, Glinsmann-Gibson B, McGrath M, Rimsza LM. Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature. Int J Cancer. 2019 12 01; 145(11):3078-3088. PMID: 31044434.
      View in: PubMed
    15. Saha D, Kharbanda A, Essien , Zhang , Cooper R, Basak D, Kendrick S, Frett B, Li H. Intramolecular cyclization of imidazo[1,2-a]pyridines via a silver mediated/palladium catalyzed C–H activation strategy. Organic chemistry frontiers. 2019; 2234.
    16. Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 08 10; 60(15):6587-6597. PMID: 28605593.
      View in: PubMed
    17. Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch. 2017 Jan; 470(1):113-117. PMID: 27888357.
      View in: PubMed
    18. Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2016; 57(3):717-20. PMID: 26437080.
      View in: PubMed
    19. Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, Rimsza LM, Puvvada SD, Schatz JH. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015 Aug; 29(8):1702-12. PMID: 25882699.
      View in: PubMed
    20. Kendrick SL, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt LM, Chan WC, Steidl C, Grogan TM, Rimsza LM. BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol. 2014 Oct; 45(10):2144-53. PMID: 25090918.
      View in: PubMed
    21. Kendrick S, Kang HJ, Alam MP, Madathil MM, Agrawal P, Gokhale V, Yang D, Hecht SM, Hurley LH. The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc. 2014 Mar 19; 136(11):4161-71. PMID: 24559410.
      View in: PubMed
    22. Kang HJ, Kendrick S, Hecht SM, Hurley LH. The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules. J Am Chem Soc. 2014 Mar 19; 136(11):4172-85. PMID: 24559432.
      View in: PubMed
    23. Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet. 2013 Jul-Aug; 206(7-8):257-65. PMID: 24080457.
      View in: PubMed
    24. Valentino C, Kendrick S, Johnson N, Gascoyne R, Chan WC, Weisenburger D, Braziel R, Cook JR, Tubbs R, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe E, Zhang W, Brunhoeber P, Nitta H, Grogan T, Rimsza L. Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. Am J Clin Pathol. 2013 Feb; 139(2):242-54. PMID: 23355209.
      View in: PubMed
    25. Wang L, Rodrigues NA, Wu Y, Maslikowski BM, Singh N, Lacroix S, B?dard PA. Pleiotropic action of AP-1 in v-Src-transformed cells. J Virol. 2011 Jul; 85(13):6725-35. PMID: 21507983.
      View in: PubMed
    26. Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. FEBS J. 2010 Sep; 277(17):3459-69. PMID: 20670278.
      View in: PubMed
    27. Kendrick S, Hurley LH. The role of G-quadruplex/i-motif secondary structures as cis-acting regulatory elements. Pure Appl Chem. 2010 Jan 01; 82(8):1609-1621. PMID: 21796223.
      View in: PubMed
    28. Kendrick S, Akiyama Y, Hecht SM, Hurley LH. The i-motif in the bcl-2 P1 promoter forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc. 2009 Dec 09; 131(48):17667-76. PMID: 19908860.
      View in: PubMed
    29. Richardson M, Wong D, Lacroix S, Stanisz J, Singh G. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). Cancer Chemother Pharmacol. 2005 Jul; 56(1):1-9. PMID: 15726364.
      View in: PubMed
    Kendrick's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (187) concept(s)
    _
    Co-Authors Expand Description
    See all (24) people
    _
    Similar People Expand Description
    See all (38) people
    _
    Same Department Expand Description
    Search Department